Harvard Bioscience ( (HBIO) ) just unveiled an update.
On April 10, 2025, Bertrand Loy announced he will not seek re-election at Harvard Bioscience‘s 2025 Annual Meeting, ending his tenure that began in 2014. His departure is not due to any disagreements with the company, and he will continue his roles until the meeting, with the Board expressing gratitude for his service.
Spark’s Take on HBIO Stock
According to Spark, TipRanks’ AI Analyst, HBIO is a Underperform.
Harvard Bioscience is currently facing considerable financial challenges, including declining revenue and profitability issues, which are further compounded by negative technical trends and valuation concerns. While there are opportunities such as strategic partnerships and product launches, these are overshadowed by significant risks including debt covenant non-compliance and management changes, resulting in a low overall stock score.
To see Spark’s full report on HBIO stock, click here.
More about Harvard Bioscience
YTD Price Performance: -80.54%
Average Trading Volume: 330,938
Technical Sentiment Signal: Buy
Current Market Cap: $17.44M
For a thorough assessment of HBIO stock, go to TipRanks’ Stock Analysis page.